07:00 , Jun 11, 2012 |  BC Week In Review  |  Financial News

BioCurex proposes private placement of convertible notes

BioCurex Inc. (OTCBB:BOCX), Richmond, B.C.   Business: Diagnostic   Date announced: 5/31/12   Type: Private placement of convertible notes   To be raised: TBD   Shares: TBD   Price prior: $0.01   Investor: Paulson Investment...
08:00 , Nov 21, 2011 |  BC Week In Review  |  Clinical News

RECAF blood test diagnostic data

Data from 81 prostate cancer patients and 61 patients with benign prostate hyperplasia (BPH), all of which had prostate specific antigen (PSA) levels between 4-10 ng/mL, showed that BioCurex's RECAF blood test had 93% sensitivity...
07:00 , Oct 31, 2011 |  BioCentury  |  Regulation

Lessons from PSA debate

While the medical community debates a U.S. task force's recommendation against PSA screening for prostate cancer, the implications are far broader: The task force's methodology for subjectively balancing benefit and harm is being applied to...
07:00 , Oct 3, 2011 |  BioCentury  |  Finance

Value verification

Buysiders are looking for strong data from a handful of high-profile compounds to drive their returns this quarter and to improve their 2011 performance. Infectious disease company Pharmasset Inc. provided a head start on the...
07:00 , Jul 25, 2011 |  BC Week In Review  |  Company News

BioCurex management update

BioCurex Inc. (OTCBB:BOCX), Richmond, B.C.   Business: Diagnostic   Hired: Paul Slowey as president  ...
07:00 , Jul 4, 2011 |  BC Week In Review  |  Clinical News

RECAF blood test diagnostic data

A retrospective analysis of 167 ovarian cancer patients and 106 healthy controls showed that BioCurex's RECAF blood test in combination with the CA125 biomarker had 83% sensitivity for detecting ovarian cancer vs. 52.5% and 70%...
08:00 , Feb 7, 2011 |  BC Week In Review  |  Company News

Immune Network, Immunitor deal

Immune Network plans to acquire Immunitor in a stock exchange deal. Immune Network will receive 50% of Immunitor's stock in exchange for 50 million Immune Network shares, valued at $2.1 million based on Immune Network's...
07:00 , Jul 26, 2010 |  BC Week In Review  |  Clinical News

RECAF blood test: Data

A trial of blood samples from 27 patients with early stage breast cancer and 15 healthy controls showed that BioCurex's RECAF blood test had 96% sensitivity and 93% specificity for breast cancer at a standard...
07:00 , Apr 5, 2010 |  BioCentury  |  Finance

2Q Financial Markets Preview: Wanted Dry Powder

Biotech run-ups have historically cooled after 25-30% gains. Thus the question going into the second quarter is whether there's momentum to keep going, or whether the sector will take a breather. The historical numbers are...
08:00 , Feb 22, 2010 |  BC Week In Review  |  Company News

BioCurex sales and marketing update

BioCurex launched OncoPet RECAF in North America, Europe and China to detect cancer in dogs. The test detects the alpha fetoprotein (AFP) receptor (RECAF) in blood. The company said the assay used in the veterinary...